Stockscreener 앱 받기
4.53
2.16%
-0.10
시간 외 거래:
4.46
-0.07
-1.55%
전일 마감가:
$4.63
열려 있는:
$4.67
하루 거래량:
1.83M
Relative Volume:
0.20
시가총액:
$353.59M
수익:
-
순이익/손실:
$-209.96M
주가수익비율:
-1.4335
EPS:
-3.16
순현금흐름:
$-176.27M
1주 성능:
-4.23%
1개월 성능:
-24.37%
6개월 성능:
-34.54%
1년 성능:
-59.26%
1일 변동 폭
$4.495
$4.73
1주일 범위
$4.495
$4.95
52주 변동 폭
$2.68
$17.00
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
REPL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
4.53 | 361.40M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
Why Replimune Group Inc. is moving todayMarket Sentiment Report & High Accuracy Swing Trade Signals - newser.com
Forecasting Replimune Group Inc. price range with options data2025 Technical Patterns & Risk Managed Investment Signals - newser.com
How to use a screener to detect Replimune Group Inc. breakoutsInsider Selling & Technical Entry and Exit Tips - newser.com
Will Replimune Group Inc. stock go up soon2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com
Tools to assess Replimune Group Inc.’s risk profileMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Real time social sentiment graph for Replimune Group Inc.Dollar Strength & AI Powered Market Entry Ideas - newser.com
Will a bounce in Replimune Group Inc. offer an exit2025 Pullback Review & Capital Efficient Trade Techniques - newser.com
Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Published on: 2025-10-05 07:01:13 - newser.com
What does recent volatility data suggest for Replimune Group Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com
Why retail investors pile into Replimune Group Inc. stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com
Published on: 2025-10-03 06:54:08 - newser.com
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat
Strategies to average down on Replimune Group Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Will Replimune Group Inc. stock sustain high P E ratios2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize
Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News
Investigation announced for Long-Term Investors in shares - openPR.com
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - FinancialContent
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism By Investing.com - Investing.com South Africa
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune’s SWOT analysis: biotech stock faces FDA hurdles amid sector optimism - Investing.com
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law Firm - PR Newswire
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pend - GuruFocus
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsREPL - WV News
2025-09-22 | Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky | NDAQ:REPL | Press Release - Stockhouse
Replimune Group, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsREPL - MarketScreener
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Se - GuruFocus
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Replimune Shares Plummet Amid Regulatory Crisis and Mounting Litigation - AD HOC NEWS
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, - GlobeNewswire
REPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% - GlobeNewswire
REPL DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Replimune Group, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
5.74%
자본화:
|
볼륨(24시간):